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Introduction 
The process of scientific publication, through peer-review, is largely one of trust. 
There is no reason to assume a scientist came to his conclusions through fraudulent 
means and it is assumed by many that the peer-review process will bring to light any 
inaccuracies. However, it is not unusual to unearth tales of fraud and misconduct in the 
scientific literature. These can include anything from fabrication of data to plagiarism to 
distortion of actual data. Evidence of misconduct will lead to an investigation of that 
scientist’s work and ultimately, if proven invalid, the publication is retracted. 
A retraction is simply a statement, usually, but not necessarily, issued in the 
original journal of publication but not necessarily, informing the readers that a previously 
published paper has been proven invalid. It is typically issued by the original authors but 
in special cases, can also be retracted by the authors’ institution or the journal editor. 
Since the retraction is printed in a subsequent issue, there is no indication in the original 
print journal that this article has been retracted, so there is nothing to stop the reader of 
the article from using it as a reference in his own manuscript as if it were valid. In the 
electronic environment it is easier to link retraction statements to original articles so there 
is less chance that a reader will assume a retracted article is a valid piece of scientific 
research. 
Scientific error can be intentional, including fabrication of data or plagiarism, but 
it can also be unintentional. Not all article retractions are the result of misconduct; 
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sometimes it is simply a mistake too large to be rectified by printing a correction. Even 
with this admission of an honest mistake, the reputations of both the scientist and the 
journal are called into question. Even if the article is known to be fraudulent, “the 
business of declaring a biomedical paper flawed and retracting it from the body of 
literature is an inexact undertaking, fraught with legal, ethical, and scientific 
complications” (Snodgrass and Pfiefer 332).  
It is important to know the way information is disseminated in scientific research 
to understand how fraudulent research is perpetuated in the literature as if it were valid. 
There are several ways researchers find information on their topic of choice. One is by 
doing a literature search through a database like MEDLINE or Web of Science. Another 
way is by culling through the reference lists of articles they have found useful. 
Researchers can also find articles by word of mouth from colleagues or reviewers, 
recommendations from librarians and by browsing the current literature in their field. 
These are just a few methods for finding information in the sciences, but not all of these 
methods of research would inform the researcher if he were using a source which had 
been retracted. 
The National Library of Medicine has been tagging retracted publications in their 
MEDLINE database with the heading “Retracted Publication” since 1984 and they also 
link the retraction statement to the original article, as they would do for a comment or 
erratum. Other scientific databases, such as the Institute for Scientific Information’s (ISI) 
Web of Science, do not link retractions to their original article, so a researcher would not 
know if an article had been retracted when using these databases to find research on their 
topic. Some publishers also create a link between the retraction and the original article in 
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their electronic versions of the journal, but not all do and there is inconsistency among 
the publishers as to how this is accomplished. If a researcher were to cull references of 
other articles or browse the print journals to find relevant research, he or she would not 
necessarily be alerted to a retraction. 
There is a very good chance a researcher would stumble upon a retracted article 
without ever knowing it had been proven invalid and use it as if it were a valid source. 
Then the researcher could unknowingly use this retracted paper to support his or her 
research or validate an idea, unaware that this article is of questionable validity. Citing a 
retracted paper not only has negative implications for the citing author’s work, but also 
further muddies the scientific record. Theoretically, once an article has been retracted, 
there should not be any more citations to this work unless it is cited negatively or its 
retraction is acknowledged in the text. But, is there any way to get a sense of how often 
invalid research is being cited after it has been retracted? 
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Literature Review 
In trying to understand a topic, authors look at what has previously been written. 
When they write on that subject, they create links to those resources in the form of a 
citation. Small explains a citation as, “when we attempt to express ourselves on a topic, 
and in our train of thought, come to an idea which is in our mind associated with a 
specific source” (339). Citations are used to attribute ideas to the source from which they 
came. Several people have studied the field of citation behavior to better understand the 
reasons authors cite certain works. 
Shadish et al. studied author judgments of works they had chosen as references 
and found several motivations behind using a specific resource for citation. They 
surveyed 192 authors in the field of psychology to try to assess the most important 
reason, out of 28 reasons, those authors chose to cite one specific article in their reference 
list. They found that 18% chose “this reference supports an assertion in the sentence in 
which it occurred,” 16% said “this reference documents the source of a method or design 
feature used in [the] study,” and 9% said “it was a classic reference in the field” (481). 
The study also found that 45% of the citing authors had either spoken directly or by 
phone with the referenced author (483). This study helps explain the basis on which 
authors chose works to cite in their writing. 
In another article about citation behavior, Michael and Barbara MacRoberts 
explain why negative references are infrequently seen in the literature. The authors 
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present several reasons which could explain this hesitancy to criticize a colleague in 
print; the colleague in question could be a friend or superior, “editors routinely send 
manuscripts to the very person or persons being criticized,” or criticism is not necessarily 
well received by editors who sometimes want it toned down before publication (92). The 
MacRoberts’ conclude that it would be “almost impossible to detect all negational 
references without author cooperation” (93). 
 Studies of citations and citation behavior can be carried out using a citation index. 
According to Eugene Garfield, founder of the Institute for Scientific Information, the 
oldest citation index still in existence is Shepard’s Citations, which was first published in 
1873 to aid the legal profession in searching the case literature (Citation Indexing 7). The 
first annual edition of ISI’s Science Citation Index was published in 1963 and Garfield 
credits Shepard’s Citations as being his inspiration (Citation Indexing 18). 
 Citation indexes use the citations of works to provide access to the literature. 
When an author cites a work, it is assumed that the two articles have something in 
common, and citation indexes rely on this linkage rather than the subject or keyword 
indexing used by MEDLINE and other databases. Citations can be used as “measures of 
scientific accomplishments of an individual, a group, an institution, or a country, as well 
as for following the temporal evolution of science in general, or a certain field of science 
in particular” (Moravcsik 86). 
Several studies have investigated the context in which works are cited in papers. 
Moravcsik and Murugesan created a classification scheme of references to better 
understand the context in which papers were being cited. Citations were labeled 
conceptual or operational, organic or perfunctory, evolutionary or juxtapositional, and 
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confirmative or negational (88). This classification was developed to study articles in 
theoretical high energy physics, but has also been applied in contextual analyses of 
publications in other fields. 
Inspired by the Moravcsik-Murugesan study, Chubin and Moitra focus on 
classifying citation context as affirmative or negational. Affirmative citations can be 
either essential or supplementary and negational citations are either partial or total (426-
427). The authors found that 95% of their citations fell into the affirmative categories and 
only 5% were negational (429).  
There are few studies that explore the citation history of retracted articles. Three 
papers investigated citations to articles written by three specific authors whom were 
proven to have committed scientific fraud and misconduct. All three authors wrote many 
articles and their cases of fraud were well publicized in the literature. Garfield and 
Welljams-Dorof used ISI’s Science Citation Index to identify citations made to 23 articles 
authored by Stephen Breuning. They excluded instances where Breuning cited himself 
and analyzed the remaining citations to determine if Breuning’s work was mentioned 
positively, negatively or neutrally. They found that 57.4% of the citations were neutral, 
only mentioning some aspect of his work, 32.3% were negative and 9.9% were positive 
(1426). 
The second case, studied by Kochan and Budd, used the Science Citation Index to 
determine post-retraction citations to the literature of John Darsee, who was found to 
have falsified much of his data. His work was proven invalid in 1981 (489). Similar to the 
Garfield and Welljams-Dorof study of the Breuning case, the authors studied citations to 
Darsee in the period from 1982-1990 and performed citation context analysis to see if 
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they were positive, negative, or mention fraud. The authors found that 85.9% of the 
citations were positive, 8.4% negative, and 5.7% made mention of the fraud (491). The 
authors acknowledged different findings from the earlier study and said “it is obvious that 
Garfield and Welljams-Dorof’s finding cannot be extrapolated to all cases of fraud” 
(491). Although citations began to taper off after several years, the authors found that 
there were still positive citations to Darsee’s work up to ten years after the discovery of 
the fraud. 
The third case studied was the Robert Slutsky case, investigated by Whitley, 
Rennie and Hafner. The authors chose 86 of Slutsky’s articles published in five journals 
and looked at the citations to these articles in an 11 year period, from 1979 to 1990. 
Slutsky resigned from his position as a cardiologist in 1985 so the authors were analyzing 
citations to Slutsky before and after his work was proven to be invalid to see if there was 
any tapering off of citations to his work post-retraction. The authors compared the 
citation performance of each of Slutsky’s articles to two articles from a control group, 
appearing in the same issue as the Slutsky article, to try to understand any impact 
retraction had on the citation life of his papers. The authors found that the citations to 
Slutsky articles were reduced after they were exposed as invalid (173). 
In her dissertation, Wright studied 53 retracted articles to see if citations to those 
papers went down after the retraction, by comparing the number of citations two years 
before and after retraction and comparing that to the normal rate of decline for citations 
due to obsolescence. She found that there was a statistically significant difference 
between the number of pre- and post-retraction citations (223). Secondly, Wright 
performed citation context analysis on over 300 articles which cited the retracted papers 
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to see if they were being cited positively or negatively. The author found that only about 
10% of the citations to these retracted papers were negative (234). 
A study by Pfiefer and Snodgrass chose 82 retracted articles and analyzed 
citations to these articles. The authors identified 733 citations to these 82 articles and 
looked at the impact factor of the citing journal, the geographic distribution of citing 
author, and the number of cumulative citations versus how many years had elapsed since 
the retraction. Also, interestingly, the authors found that only 56% of their 82 articles 
were tagged with the “Retracted Publication” heading in the MEDLINE database (1422).  
Snodgrass and Pfiefer also looked at the standardization of retraction notices in the 
scientific literature. The authors concluded that, despite guidelines in place to establish 
some unity among retraction notices, out of 35 retraction notices, only one adhered to all 
of the guidelines (331). They found that “too many retractions, roughly half, continue to 
be published as letters to the editor,” and “significant format problems remain” (331). 
Further information about MEDLINE retraction policies can be found in Atlas 
and in the National Library of Medicine’s fact sheet, “Errata, Retraction, Duplicated 
Publication, and Comment Policy.” Their policy on retractions is that a retraction will 
only be indexed as such if “it clearly states that the article in question is being retracted or 
withdrawn, and is signed by an author of the retracted paper or the author’s legal counsel; 
by the head of the department, dean or director of the laboratory where the paper was 
produced; or by the journal editor” (4). In addition, it “must be labeled and published in 
citable form; that is, the retraction must appear on a numbered page in an issue of the 
journal that published the retracted article” (4). The National Library of Medicine (NLM) 
is requiring publishers to print retractions in a very specific way, so it is not surprising 
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that Pfeifer and Snodgrass found that 44% of their retracted articles were not labeled as 
such in the MEDLINE database. In response to NLM issuing these guidelines, the 
International Committee of Medical Journal Editors (ICMJE) met to establish their own 
set of rules to comply with NLM so retractions can be indexed in the proper way and be 
effectively communicated. They decided “the retraction, so labeled, should appear in a 
prominent section of the journal, be listed in the table of contents page, and include in its 
heading the title of the original article” (304). Publishers are not required to follow these 
guidelines and it seems, even today, there is little consistency among scientific, medical 
and technical (STM) publishers. 
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Methodology 
 This study of retracted papers has two aims: 1) to see if retracted articles in the 
scientific, technical and medical literature are still being cited, and 2) to look at the 
citations to four retracted papers to get a sense of whether the context of the references is 
positive or negative. 
 A study of the medical literature was chosen because the MEDLINE database can 
be used to easily locate retracted publications because retracted articles are tagged with a 
MeSH heading specific to retraction. To identify the retracted publications used for this 
study, the MEDLINE database available through PubMed was used, and all of the 
citations for the years 1994 to 2000 with the MeSH heading “Retracted Publication” as a 
publication type were imported into the reference management software EndNote. 
Because citations to these papers were being studied, it was decided not to choose any 
retracted articles more current than the year 2000 to ensure there was enough time for 
significant citations to accrue. In addition to using PubMed to find retracted papers, the 
Office of Research Integrity (ORI) Newsletter and the NIH Guide for Grants and 
Contracts website (http://grants.nih.gov/grants/guide/index.html) were searched for those 
years to ensure there were none missed by PubMed. Only one additional paper was 
identified this way.  
 Once the pool of 211 retracted articles was established, PubMed was used to 
identify the date of retraction and the citation of the retraction statement. Then, ISI’s 
 12
Science Citation Index was used to ascertain the total number of citations and the number 
of citations post-retraction for each retracted article. Based on the method used by Pfiefer 
and Snodgrass, the citations post-retraction were counted starting the next calendar year 
after the retraction was published (1420).  
 Four retracted articles were then chosen as case studies to perform citation context 
analysis on the references to those four cases. The cases were chosen because of oddities 
or a high number of citations to the article after retraction. From Science Citation Index, 
the bibliographic information of the citations to each article was downloaded, separately 
for each of the four articles, into an EndNote file. All articles not in English were 
eliminated before context analysis. The 137 referent articles were analyzed according to 
Chubin and Moitra’s study design. The citation was found in each article and the context 
was determined as affirmative or negational. The authors categorize a citation as 
affirmative if it is “declared central to the reported research, a reference on which its 
findings depend” or “provide[s] additional information” (427). A negational reference is 
if “a citer suggests that the paper is erroneous in part” or when the “citer refers to the 
paper as being completely wrong” (427). These definitions were used in categorizing the 
context of references to the retracted articles. 
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Results 
Large set of retracted papers 
 There were 211 retracted articles identified for the first part of this study. They 
were originally published in the years 1996 to 2000 and all retracted by 2004. These 
articles had a total of 7,937 citations with 2,393 of the citations published after retraction. 
On average the articles were cited 11.3 times after retraction and 37.6 times in total, 
which shows that about 30% of the articles’ citations were after retraction. Also, eight of 
the 211 articles were never cited and 28 articles, about 13.3%, were not ever cited after 
retraction. 
Case studies 
 Four retracted articles were chosen for case studies. Two were chosen because of 
the oddity of their retractions, one because of its high proportion of citations after 
retraction, and the last because it was highly publicized. The post-retraction citations to 
these four retracted articles were examined to determine the context of the references. 
The following are the four articles chosen as case studies: 
Buchdunger, E., et al. "Selective Inhibition of the Platelet-Derived Growth Factor 
Signal Transduction Pathway by a Protein-Tyrosine Kinase Inhibitor of 
the 2-Phenylaminopyrimidine Class." Proc Natl Acad Sci U S A 92.7 
(1995): 2558-62. 
Schon, J. H., et al. "A Light-Emitting Field-Effect Transistor." Science 290.5493 
(2000): 963-6.
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Sparks, L. E., et al. "Volatile Organic Compound Emissions from Latex Paint--
Part 1. Chamber Experiments and Source Model Development." Indoor 
Air 9.1 (1999a): 10-7. 
---. "Volatile Organic Compound Emissions from Latex Paint--Part 2. Test House 
Studies and Indoor Air Quality (Iaq) Modeling." Indoor Air 9.1 (1999b): 
18-25. 
Case Study 1: Two papers by Sparks et al. 
 The first two articles were both retracted papers by the same authors and were 
published in the same issue of the journal Indoor Air. These two articles were chosen 
because of the nature of their retraction. In examining the June 2000 retraction statement, 
it was found that these two articles were retracted simply because of an issue of 
trademark. As explained by editor-in-chief of the journal Indoor Air, David Grimsrud, the 
journal published four papers “that used TEXANOL® and TXIB® as generic names for 
the chemicals 2,2,4-trimethyl-1,3-pentanediol monisobutyrate and 2,2,4-trimethyl 1,3-
pentanediol diisobutyrate. TEXANOL® and TXIB® are registered trademarks of the 
Eastman Chemical Company” (136). Two of the four papers retracted from this issue of 
Indoor Air were by Sparks et al. 
 The reason this retraction is so unusual is because there is no error or flaw in the 
paper itself, just in the choice of a few words. It seems like the kind of problem that could 
easily be made right with a correction, but for some reason, possibly legal, the journal 
decided to completely retract the four articles. In this case, there is nothing to indicate the 
research published in these two studies is invalid but because of the retraction of the 
articles, they should be stricken from the literature and cited accordingly. 
 The lists of papers referencing these two articles are in Appendix A, citing the 
article beginning on page 10, and Appendix B, citing the article beginning on page 18. 
The result of the context analysis performed on the references is summarized in Table 1. 
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One article was removed because it was not in English and the context of the citation 
could not be determined. For the first article, 15% of the citations, or two references out 
of ten, were found to be negational citations. Neither negative reference mentioned the 
retraction. For the second article, none of the five references were negational. 
 
Table 1: Analysis of post-retraction citations to Sparks et al. (1999a, 1999b) 
  Sparks et al. (1999a) Sparks et al. (1999b) 
Type of citation Frequency Percent Frequency Percent
Affirmative 10 77% 5 100%
Negational 2 15% 0 0%
Eliminated 1 8% 0 0%
Total 13 100% 5 100%
 
 When examining the citations to the first article, two were published in the same 
journal as the retracted article (Fjallstrom, et al.; Yang and Chen). The editors of this 
journal must not have noticed that articles accepted for publication in their journal were 
citing an article that they had just retracted a few years earlier. 
Case study 2: Buchdunger et al., 1995 
 The next case study was chosen because a high proportion of the citations came 
after the retraction. The article has been cited 148 times since publication, with 100 of 
those citations coming post-retraction (see Appendix C for post-retraction citations). In 
their retraction, the authors state, “In the interest of scientific accuracy and our mutual 
desire with the editors that only high quality and reliable data are published, we regret to 
say that the in vivo data for the articles above are not considered reliable” (12069). This is 
a more typical retraction than the retraction of the first two articles; it states that an aspect 
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of the experiment could not be reproduced or verified so the authors are retracting the 
article. 
 It was found in this case that most of the citations to the article were affirmative, 
as seen in Table 2. Six articles were eliminated because they were in a foreign language 
or because a copy could not be located. The remaining 94 citations were analyzed and 93 
were affirmative while only one was negational. Although location of the reference in the 
article was not specifically studied, in many of the articles, the reference was made to 
support some part of the author’s methodology. 
It was also interesting to see that the author of the retracted article, Buchdunger, 
cited this retracted work in six of her subsequent publications. As she was the first author 
listed on the retraction, it is hard to imagine that she would not know she was citing a 
retracted article in her subsequent articles. 
Table 2: Analysis of post-retraction 
citations to Buchdunger et al., 1995 
Type of citation Frequency Percent
Affirmative 93 93%
Negational 1 1%
Eliminated 6 6%
Total 100 100%
Case study 3: Schon et al., 2000 
 The last case was chosen because it was a very high-profile case, with proven 
misconduct and several of the author’s articles being retracted. The first author, Hendrik 
Schon, was a physicist at Bell Labs, owned by Lucent Technologies. An article in Wired 
says he has published more than 80 articles before the age of 32, many in high-impact 
journals like Science and Nature (1). The final report issued by Bell Labs in the 
investigation into Schon’s work listed his work in three categories of misconduct: 
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substitution of data, unrealistic precision of data, and results that contradict known 
physics (2). The committee found misconduct in 16 of Schon’s articles and recommended 
their retraction and also cleared all coauthors of any responsibility (3-4). This was a very 
well-publicized case of misconduct, with much coverage in the scientific news and on the 
Internet. It is important to perform citation context analysis on references to a Schon 
article to see if a retracted paper with so much publicity is still receiving citations. 
 The article chosen was cited 19 times after retraction and 60 times in total since 
publication; for a bibliography of post-retraction citations see Appendix D. A further 
examination of these citations revealed that 17 of the citations were affirmative and only 
two negational, which means 11% of the citations are negative (see Table 3). Both of the 
negative citations mention the retraction. 
Table 3: Analysis of post-retraction 
citations to Schon et al., 2000 
Type of citation Frequency Percent
Affirmative 17 89%
Negational 2 11%
Eliminated 0 0%
Total 19 100%
 
It was surprising to see an article (Meng, et al.) with two of the listed authors from 
Lucent Technologies, where Schon worked at the time the scandal erupted. The reference 
to Schon’s work in this article was positive. One would expect that those authors would 
have known of the scandal or any internal review process would have caught the 
inappropriate reference. 
 The referring articles in this case study were also analyzed for location of the 
authors because it was thought that maybe authors outside of the United States would not 
receive the same exposure to the news of the Schon scandal. It was found that 16 of the 
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19 articles, about 84%, had author addresses outside of the United States, which could 
easily contribute to the authors’ lack of knowledge about the retraction. 
 Another interesting finding in this case was that two of the articles (Xie et al.; 
Kim et al.) cited several of Schon’s works in their papers. In fact, in both articles, 6 of the 
10 references were to Schon articles. If their work is so based on work that has been 
proven invalid, one has to wonder about the validity of their two studies. It is easy in 
these cases to see how much citations to fraudulent research can taint the results of 
subsequent papers. 
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Discussion 
 The study of a large group of retracted articles showed that retracted papers are 
still being cited with some regularity. A further examination of these citations, with 
respect to context, found that the majority of these citations were positive, indicating that 
the fact that the article was retracted was either not known or not understood by the citing 
authors. 
 The case studies illustrated that, even in the case of references to retracted 
articles, there are very few negative citations. There was variance in the percentage of 
negational references in the four cases, ranging from 1% negative references to 
Buchdunger et al. to 15% citing Sparks et al. (1999a). The two Sparks articles and the 
Schon article had significantly fewer citations to study, so one negative reference would 
affect the ratio of positive to negative citations more than the Buchdunger article with 
100 citations. 
 While there were few negative citations found in the case studies, there were also 
few mentions of retraction in works citing these retracted articles. Of the 137 citing 
articles analyzed for context in the case studies, only five were negative citations, and of 
those five, only two mention the retraction. None of the affirmative citations mention the 
retraction. The two negative citations to Sparks et al. (1999a) questioned the complexity 
of the authors’ method (Guo; Yang et al.). The two negational citations to Schon et al. 
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referred to his study but also stated that the findings could not be reproduced and that the 
work was subsequently retracted (Chen et al; Hepp et al.). 
 Comparing the number of negative citations in this study to similar studies it is 
seen that the results are fairly consistent. The Kochan and Budd study found 8.4% of 
citations to their retracted articles were negative, Wright found about 10% of citations to 
retracted papers to be negational, and Garfield and Welljams-Dorof found 32.3% were 
negative citations. In the present study, the range of negational citations to the retracted 
case studies was between 0% and 15% for the four articles chosen to study. 
 It would be interesting to compare the post-retraction citations with a control 
group to get a better understanding of whether or not any decline in citations is because 
of the retraction or if it is a normal drop off of citations due to aging or obsolescence. The 
Schon article’s post-retraction citations seemed to drop off steeply, as seen in Chart 1, but 
presumably that is because of the story’s coverage in the scientific news. 
Chart 1: Citations to Schon et al. by year
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 A limitation of this study is the author’s lack of subject specialty for the context 
analysis. Many articles have obvious clues in terms of referencing, but subject specialty 
would unearth the subtleties of language used and a better understanding of the true 
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context of the reference. As noted by MacRoberts and MacRoberts, not only is it difficult 
to assess the citation’s context, but even negative references are sometimes veiled to 
appear positive.  
 Another important aspect of the study’s methods was that there was not one 
specific scientific subject chosen for this study. Since all retracted articles were taken 
from MEDLINE, they come from a broad range of scientific topics. In a future study, it 
may be fruitful to choose a specialty, like genetics or oncology, to study so that only one 
specialist would be needed to perform the citation context analysis. 
 Another limitation of this study is the availability of only one citation index, 
Science Citation Index (SCI), to find the articles that refer to the retracted papers. 
Although SCI indexes a wide variety of scientific, technical and medical journals, they do 
not include all journals in their database and do not index books’ or conference 
proceedings’ citations, so it is likely that references could be missed, especially from 
journals published outside of the United States and Western Europe. Science Citation 
Index also suffers from misspellings in author references, so it is not easy to locate all of 
the references to a certain article. 
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Conclusion 
 It has been shown that positive citations to retracted articles continue in the 
scientific, technical and medical literature. As previously discussed, this could be a 
problem with the way the news of a retraction is disseminated. Because retractions are 
announced in a subsequent issue of the journal, there is no indication of the retraction in 
the original print copy of the article. It is not surprising that researchers do not know their 
sources have been retracted. It was interesting to study the citations to a highly-publicized 
case, citations to the Schon article, because it showed that even an abundance of news 
coverage did not keep people from still citing his work positively. 
 The emergence of the Internet and the availability of electronic journals and 
online databases for searching present an opportunity for more linkage of retraction 
statements to the article being retracted. The MEDLINE database has been a leader on 
this front and hopefully more databases and publishers will follow suit. Electronic 
counterparts of print journals could very easily link the article with its retraction but still 
many do not. 
 It is equally important that authors and editors check the reference lists in articles 
before publication. Not only do they need to check for misspellings and errors, but one of 
the references could be to a work proven to be invalid. A good place to start would be to 
check references in the MEDLINE database. Another good resource is the Retractions 
Database (http://www.scc.rutgers.edu/retractions/index.cfm) available from the Scholarly 
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Communications Center at Rutgers University. It is a database of retracted articles that 
can be searched by fields like author and title. It does not seem, at this time, that there is 
an adequate amount of reference checking done before publication. 
 Hopefully this problem will get better in the future, with the opportunities for 
more communication of retractions presented by the increased use of online 
environments for scholarly communication. Citations to retracted articles affect the 
scientific record in a harmful way so it is important that these retractions be more 
effectively communicated. 
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